We are excited to commence the work to develop the Roadmap for a National Targeted Skin Cancer Screening Program, and proud to be leading such an important endeavour for the Australian community.
Skin checks are an important tool in the early detection of skin cancers. MIA & others in the skin cancer community have advocated for a more systematic, targeted & equitable approach to skin cancer screening in Australia. As a result, the Australian Gov't has allocated $10m for development of a Roadmap for a National Targeted Skin Cancer Screening Program.
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.
We are proud to announce that the ground-breaking work of the MIA team has been recognised with two prestigious 2024 NSW Premier’s Awards for Outstanding Cancer Research.
Patients, and families of patients, impacted by advanced melanoma are invited to participate in an online interview to explore their views, experiences, and needs related to genetic information, support and testing.
Hosted by MIA in Sydney, AMC2024 brought together 776 multidisciplinary delegates to engage in insightful discussions, presentations and workshops, all dedicated to reaching our common goal of zero deaths from melanoma. See our AMC2024 photo album.
This World Cancer Research Day, the NSW Government is committing $2.1 million in research grant funding, with almost $700k awarded to MIA's Prof Long for an imaging system that will allow researchers to better visualise & understand tumour cell interactions.
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers across the globe.
